A new Bayesian system called ALADYNOULLI is designed to forecast how multiple diseases unfold over time from longitudinal electronic health record (EHR) histories. The work targets a central challenge in longitudinal modelling: evaluating prediction without “information leakage,” so that future diagnoses never influence training for past timepoints. By explicitly simulating real clinical follow-up, the researchers aim to make risk estimates more trustworthy for decision-making.
In the primary assessment, ALADYNOULLI produced dynamic 1-year forecasts at 10 fixed moments during follow-up, starting at enrollment and extending to years 1 through 9. At each timepoint, models were retrained using only data available up to that moment, then tested on 1-year outcomes. The key metric was the median area under the receiver operating characteristic curve (AUC) across these dynamic evaluations, summarizing how predictive accuracy changes as new diagnoses accumulate.
The study spans 28 diseases and reports robust discrimination for several clinically important endpoints. Performance was strong for atherosclerotic cardiovascular disease (ASCVD), breast cancer, atrial fibrillation, heart failure, and Parkinson’s disease, with AUC values of 0.879, 0.867, 0.801, 0.811, and 0.796, respectively. Importantly, the evaluation excluded people with prevalent disease at prediction time, aligning the comparisons with prospective risk.
ALADYNOULLI was also benchmarked against established clinical risk tools where feasible. At enrollment, static models trained only on baseline information were compared for both 1-year and 10-year horizons. While longer-term predictions naturally degraded, ALADYNOULLI retained meaningful power—for example, for ASCVD at 10 years—highlighting the advantage of learning from longitudinal EHR trajectories rather than relying solely on cross-sectional inputs.
Calibration analyses further supported reliability: predicted and observed event rates matched closely across millions of at-risk patient-time observations. The researchers report a mean squared error on calibration of 4.67 × 10⁻⁷, with mean predicted rates (5.55 × 10⁻⁴) closely tracking mean observed rates (5.45 × 10⁻⁴). This suggests not only ranking accuracy, but also quantitative risk realism.
To test whether results were driven by subtle temporal artifacts, the team ran sensitivity analyses that excluded events occurring shortly before prediction and varied washout windows. They also examined alternative horizons and a dynamic 10-year rolling interpolation strategy, which updates risk estimates as annual information becomes available. Together, these checks help confirm that temporal patterns are being learned in a causally aligned manner.
Overall, the findings position ALADYNOULLI as a clinically relevant framework for multi-disease risk forecasting, combining longitudinal EHR modelling with predictive discrimination and calibration. By rigorously preventing leakage and validating dynamic follow-up scenarios, the approach offers a pathway toward more actionable, time-aware risk prediction in real-world healthcare settings.
Subject of Research: Longitudinal EHR-based multi-disease risk prediction using Bayesian modelling and genetic/EHR integration Article Title: A Bayesian framework for longitudinal EHR and genetic discovery. Article References: Urbut, S.M., Ding, Y., Nakao, T. et al. A Bayesian framework for longitudinal EHR and genetic discovery. Nature (2026). https://doi.org/10.1038/s41586-026-10780-5 Image Credits: AI Generated DOI:https://doi.org/10.1038/s41586-026-10780-5 Keywords: longitudinal EHR, Bayesian framework, disease risk prediction, dynamic forecasting, temporal validation, calibration, AUC, ASCVD
New blood vessels flood the developing brain, then must be sculpted into a functional network. In the cortex, this pruning depends on selective elimination of redundant connections, but the cellular command center behind vascular refinement has remained only partly understood. A new study now points to microglia—the brain’s immune sentinels—as active architects of cerebrovascular pruning during postnatal development.
Using live visualization in the frontal cortex of postnatal day 11 mice, researchers tracked how microglia behave around forming blood vessels. They observed that microglia do not merely associate with vasculature; instead, they progressively migrate toward vessels as development proceeds. As vessel remodeling advances, microglia become enriched at sites where pruning occurs, suggesting a causal role rather than passive surveillance.
To test function, the team manipulated microglia–vessel interactions and assessed vascular outcomes. Intervening in microglial activity altered the extent of vessel elimination, consistent with the idea that microglia mediate pruning to refine the emerging vascular map. The results connect microglial behavior directly to the efficiency and organization of the developing cortical circulation.
Central to the mechanism is an immune signaling pathway previously linked to neuronal synaptic refinement: PD-L1 and its receptor PD-1. The study identifies PD-L1–PD-1 signaling as a regulator of microglia-driven vascular pruning. When this axis was disrupted, pruning was impaired, indicating that immune checkpoint-like communication can shape vascular architecture in the developing brain.
The authors further implicate a specific molecular source from microglia. They report that microglial CD5L secretion promotes the PD-1–dependent pruning program. In other words, microglia release CD5L, engage PD-1 signaling through PD-L1 interactions, and thereby influence which vessels persist and which are eliminated.
Collectively, the work reframes cerebrovascular pruning as a neuroimmune-guided developmental process. By showing that microglia actively target redundant vasculature and by defining a PD-L1–PD-1/CD5L pathway, the study provides mechanistic evidence for how immune cells can tune vascular networks to match developing brain circuitry.
Beyond development, the findings raise broader questions about whether similar immune checkpoint signaling contributes to abnormal vascular remodeling in disease, where pruning can be either excessive or insufficient. For now, the study delivers a clear developmental role: microglia help determine what the brain keeps growing and what it discards.
A newly published study in Nature Metabolism reports that brown fat can act as a hub of molecular messaging, using secreted microRNAs to coordinate physiology across the body. Researchers focused on brown adipose tissue—well known for its role in thermogenesis—and asked whether it also participates in long-distance communication via RNA signals.
To visualize and track these messages, the team employed brown-fat–specific RNA labeling in living systems. This strategy allowed them to connect RNA production within adipocytes to downstream effects elsewhere, moving beyond correlations toward a clearer map of inter-organ RNA traffic.
The central finding is the presence of a communication network mediated by microRNAs released from brown fat. These small regulatory RNAs appear to travel beyond the tissue of origin and engage gene-regulatory pathways in other organs, effectively relaying information about metabolic state.
Functionally, the work supports a model in which microRNA “dispatch” from thermogenic fat tunes cellular programs in remote targets. Such programs likely involve post-transcriptional regulation, a process microRNAs are known to influence by pairing with complementary sequences in messenger RNAs.
Importantly, the approach does not treat microRNAs as generic circulating molecules. Instead, the labeling confirms their brown-fat origin and strengthens the link between secretory RNA dynamics and systemic physiological outcomes.
The study also highlights the specificity of the messaging: not all RNAs are equally represented, and the labeled microRNA repertoire points to organized, tissue-defined signaling rather than random leakage.
Beyond mapping pathways, the results carry implications for metabolic disease research. If brown fat microRNAs can reshape gene expression in other organs, manipulating these signals could offer a route to modulate energy balance, insulin sensitivity, or inflammatory tone.
For now, the findings provide a blueprint for how RNA labelling combined with tissue specificity can uncover hidden layers of endocrine-like communication. As techniques improve, the field may move toward a broader “RNA connectome” linking organ behavior through secreted regulatory molecules.
Researchers describe their results as evidence that brown fat is not only a metabolic engine but also an information broadcaster. In the evolving landscape of viral-style science news, this discovery underscores how tiny RNA molecules can orchestrate large-scale biological conversations.
Subject of Research: Inter-organ communication via secreted microRNAs from brown adipose tissue.
Article Title: Brown fat-specific RNA labelling reveals a network of inter-organ communication by secreted microRNAs.
Article References: Lino, M., Palermo-Ruiz, G., Efthymiou, V. et al. Brown fat-specific RNA labelling reveals a network of inter-organ communication by secreted microRNAs. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01558-0
Naked mole-rats have long puzzled biologists with their striking eusocial structure, where most adults remain reproductively suppressed while a queen controls the colony’s future. Now, a new study identifies a chemical “queen odour” that links social status to endocrine control, revealing a mammalian analogue to insect queen pheromones.
The molecule, termed IPM, is enriched by the queen and acts as the key mediator of reproductive suppression in non-breeding females. When IPM is present, circulating prolactin rises while progesterone is suppressed, locking the colony into a stable reproductive hierarchy characterized by reduced conflict and maintained group cohesion.
Crucially, the team connects this behavioural outcome to the brain. Using multiple approaches—including non-invasive functional ultrasound imaging (fUSI)—they show that IPM provokes strong activation of olfactory neurons and central neural circuits. This provides a neural substrate for how a chemical cue can trigger colony-wide physiological change, rather than relying on social learning or passive association.
The experiments also clarify sensory routing. Ablating olfaction abolishes aggression initiation and lowers prolactin levels, directly tying IPM detection to reproductive suppression. While the findings are consistent with sensing through the main olfactory epithelium, the authors note that the vomeronasal system may still contribute.
Queen removal normally destabilizes colonies, leading to aggression, reproductive competition, prolactin decline, and, in extreme cases, mortality. Yet when IPM is added to queenless bedding, the colony remains stable for months. During this period, fecal progesterone metabolite levels stay low, indicating sustained ovarian quiescence alongside elevated prolactin.
The study also addresses a longstanding paradox: transferring soiled bedding and urine from parent colonies fails to maintain suppression in isolated individuals. The authors propose that IPM’s chemistry helps explain this discrepancy. As a long-chain fatty acid ester with low volatility, IPM may persist within the colony environment but fail to travel effectively over distance or survive transfer pathways that preferentially carry other chemicals.
Comparative work extends beyond naked mole-rats. IPM is detected in breeding females of four additional Fukomys species. Although reproductive suppression mechanisms may differ across species, the presence of a similar queen-linked odorant suggests convergent chemical strategies for managing reproductive skew in eusocial mammals.
Overall, the research reframes reproduction control as a chemosensory-to-endocrine pathway: IPM activates olfactory–hypothalamic signalling, elevating prolactin and inhibiting GnRH release. This “social hormone” model offers a new principle for social evolution—chemical cues can synchronize behaviour and physiology at the scale of an entire mammal colony.
Subject of Research: Reproductive suppression and social hierarchy in eusocial mammals (naked mole-rats and related Fukomys species)
Article Title: A queen odour mediates reproductive suppression in a eusocial mammal
Article References:
Khallaf, M.A., Hart, D.W., Luo, W. et al. A queen odour mediates reproductive suppression in a eusocial mammal. Nature (2026). https://doi.org/10.1038/s41586-026-10772-5
The first X-ray ever taken of a human body, in 1895, was of Wilhelm Röntgen’s wife’s hand, wedding ring and all. One hundred and thirty years later, four amateurs orbiting Earth at roughly 17,000 miles an hour recreated that portrait — a hand, a ring, the same pale architecture of bone — except this image came down from space.
It is the first diagnostic X-ray ever captured of a human being in orbit, and it is now confirmed. A study published in Radiology, the journal of the Radiological Society of North America, reports that the crew of SpaceX’s Fram2 mission acquired anatomic radiographs during their 2025 flight, and that three independent radiologists on the ground judged the orbital images statistically indistinguishable from scans taken before launch — good enough to spot a fracture, a foreign object, or the kind of injury a crew doctor would need to see fast.
The device produced a full set of images across the multi-day flight: a phantom control object, a smartwatch, a hand, a forearm, a chest, an abdomen, and a pelvis. The scans were recorded digitally, so the crew could review them on the spot without developing film. The study was led by Dr. Sheyna Gifford, an aerospace medicine physician at Mayo Clinic, whose team had spent years working toward exactly this test.
Why X-rays, and why now
Space medicine has a physics problem. Ultrasound, the workhorse of orbital diagnostics for more than four decades, transmits sound waves through gel-coupled tissue. It works fine inside a pressurized cabin. It struggles with bone, where the internal structure often stays a mystery on ultrasound, and it does nothing for the interior of a cracked component. X-rays, being electromagnetic radiation, pass straight through.
That distinction matters as crewed missions push farther from Earth than at any time in half a century. In April 2026, the Artemis II crew traveled about 252,700 miles from Earth, breaking the distance record Apollo 13 set by accident in 1970. Lunar surface stays under Artemis III and the missions that follow will place crews days away from any hospital. A broken tibia on the Moon is not a broken tibia in Houston.
Four first-time flyers, four hours of training
The operational finding may matter as much as the clinical one. The Fram2 crew — cryptocurrency investor Chun Wang, filmmaker Jannicke Mikkelsen, engineer Rabea Rogge, and polar explorer Eric Philips — were all first-time flyers, and none were physicians. Three of them received roughly four hours of training on the portable system before launch, about the length of a morning workshop, then operated it themselves in microgravity.
That mirrors how portable X-ray already gets deployed on the ground. Gifford has pointed out that these units already run at the Kentucky Derby, on Super Bowl sidelines, and across low-resource regions worldwide, precisely because they can run on solar power and be operated by people with no medical training. Staying still enough to take a clean image in freefall was the open question, and the crew answered it.
The hardware also survived the ride. After launch vibration, re-entry heating, and a Pacific splashdown, the X-ray generator came back with only superficial structural damage. That is not a minor achievement. Most medical imaging equipment is designed on the assumption it will never leave a temperature-controlled room.
The Fram2 platform
The mission itself was an unusual choice for a first-of-its-kind medical test. The privately funded flight launched from Kennedy Space Center and became the first crewed spaceflight to fly a 90-degree polar orbit, passing from pole to pole roughly every 46 minutes at an altitude of about 265 miles. Over three and a half days, the crew ran 22 research experiments, from growing mushrooms to photographing aurora, with the X-ray work among the headline objectives.
The polar trajectory was incidental to the radiography. What mattered was the profile: a short-duration flight with untrained operators willing to serve as both subjects and technicians. That is close to the exact operational shape of a lunar sortie crew, and the International Space Station rarely offers it.
A dual-use tool
Before the orbital attempt, Gifford’s group had already flown a portable unit on a parabolic flight in 2022, showing that viable diagnostic images were possible in simulated microgravity. The orbital flight was the graduation exercise, and it extended the capability beyond bone.
The smartwatch image is the tell. An X-ray that can image a fracture can also image a suspect weld, a cracked pressure vessel, or a foreign object lodged where it should not be. Gifford has framed this as the point: for a sustained presence in space, X-rays matter not only for crew but for electronics and spacesuits, which cannot be inspected inside without either taking them apart or seeing through them. On a lunar habitat where every spare part had to be launched from Earth, non-destructive inspection is itself a life-support function.
The terrestrial implications may be larger still. Diagnostic imaging is one of the widest gaps in global health infrastructure. A device rugged enough for spaceflight, cheap enough to deploy at scale, and simple enough to run after four hours of instruction is a plausible answer to that gap — the same argument that already puts these machines in rural clinics far from any hospital.
What it does not solve
An X-ray is a diagnostic tool. It is not a treatment. A crew on the lunar surface with a confirmed compound fracture still faces the problem astronauts have always faced: the nearest orthopedic surgeon is a quarter-million miles away. The value of imaging in that scenario is triage — knowing whether to continue the mission, improvise a splint, or begin a medical evacuation that could take days.
Open questions remain. The images were taken in microgravity, not the one-sixth gravity of the lunar surface, where positioning a patient and holding source-detector geometry steady will behave differently again. Radiation exposure protocols inside a cabin already bathed in cosmic rays will need their own rulebook. And while the in-flight images matched the crew’s own preflight scans, the portable system’s ceiling against full hospital equipment is a separate question this flight did not settle.
The institutional signal
The broader story is about who is now doing this kind of work. A mission funded by a private citizen, flown on a commercial capsule, carrying a commercial off-the-shelf X-ray unit, tested by an academic medical center, produced a peer-reviewed result in a mainstream journal. NASA was not the operator. Mayo Clinic was not the launch provider. SpaceX was not the principal investigator. Each played one part, and the parts fit.
That distributed model is what lunar-era space medicine will probably look like. The Apollo-era approach — one agency, one contractor stack, one flight surgeon in mission control talking to one crew — cannot scale to the cadence of missions that Artemis, Gateway, and commercial low-Earth-orbit stations imply. A portable X-ray a non-physician can operate is a small piece of hardware. It is also a preview of the operational philosophy that will have to keep future crews alive when Houston is a light-second and a half away.
The hand that came down from Fram2 sits in the same lineage as the one Röntgen made in 1895. Same bones, same rings, the same faint gray shadow of tissue around them. One was taken in a laboratory in Würzburg. The other was taken by an amateur, hurtling over the poles, 265 miles above the planet, and it came home clear enough to read.
alternative_right shares a report from Phys.org: In a study published in Nature, LSU physicists have developed the first room-temperature quantum material capable of distinguishing and transporting different quantum states of light, overcoming one of the biggest challenges in quantum materials research. Led by Associate Professor of Physics Omar S. Magana-Loaiza, the work establishes a general design principle for engineering an entirely new class of quantum materials, opening new possibilities for quantum computing, secure communications, sensing technologies and advanced energy systems.
Apocryphal tales of its meals causing the runs have plagued Taco Bell since time immemorial. But this latest parasitic outbreak is something else entirely.
As the Washington Post reports, federal and state authorities are investigating whether the fast food chain is behind the outbreak of explosive diarrhea cases across the country — further cementing its scatological legacy.
The illness, caused by the cyclosporiasis parasite, has sickened as many as 5,100 people across the country, according to the Centers for Disease Control and Prevention. In Michigan, which appears to be the epicenter of the outbreak, over 3,700 people have been infected, state authorities said.
Taco Bell’s suspected role in the outbreak comes after reports that the chain’s Michigan locations began pulling some of its ingredients. Signs in front of the restaurants stated that they were no longer serving lettuce, cilantro, onion, pico de gallo, and guacamole due to a “nationwide recall,” though what recall they were referring to is unclear.
Health officials have so far struggled to narrow down how the parasite is spreading. While usually found on fresh produce, symptoms can take weeks to manifest, making it difficult to trace back to the source.
Lettuce has emerged as one of the likeliest culprits. In an update this week, Michigan’s chief medical executive Natasha Bagdasarian said that “early information has shown lettuce as a common product that regularly comes up during the investigation.”
“Although we do not have a definite product identified as the source of the outbreak, we want to let Michiganders know what we have learned so far so they can take steps to protect their families,” Bagdasarian added.
Federal authorities haven’t singled out any veggies yet, though acting Food and Drug Administration director Don Prater acknowledged Michigan’s fixation on lettuce.
“What I can say at this point is that we’re continuing our traceback investigation on multiple produce items, including the lettuce,” he said, per WaPo.
So far, no nationwide recalls have been made related to the outbreak. One person familiar with the federal investigation, however, praised Taco Bell’s response.
“It’s good the chain has already voluntarily stopped serving a number of items,” they told the newspaper. They added that some who became sick said they didn’t eat at the chain, suggesting that it’s not the only one responsible.
New research from Columbia University found that adults who cut their sleep by about 80 minutes for six weeks packed on a pound (0.45 kg) and moved less during the day.
Astronauts on SpaceX's Fram2 mission successfully captured diagnostic X-ray images in orbit for the first time. The milestone gives space medicine a second imaging option beyond ultrasound and could help future crews diagnose injuries, inspect equipment, and support longer missions to the moon or beyond. Popular Science reports: Commercial off-the-shelf X-ray machines like the ice cooler-sized MinXray TR90BH now allow users to perform scans on subjects far away from traditional facilities. In 2022, [Mayo Clinic researcher Sheyna Gifford] assisted in preparing a crew to successfully generate digital X-rays while experiencing microgravity during a parabolic flight. Gifford's team then spent years collaborating with SpaceX to plan another feasibility study. This time, they didn't want to operate an X-ray machine aboard an aircraft simulating the conditions in space -- they intended to use the equipment during an orbital mission.
The process was detailed in a recently published study in the journal Radiology, and focuses on last year's Fram2 mission. Instead of days of medical training, astronauts spent only four hours learning how to use their portable radiography device. They then took preflight X-rays of a hand, forearm, chest, abdomen, and pelvis ahead of their SpaceX Falcon 9 rocket launch on March 31, 2025. Once in orbit, the team calibrated the system before testing their MinXray on the same body parts as well as a smartwatch.
Once the crew returned, a trio of independent radiologists reviewed the orbital X-ray images based on their positioning, spatial and contrast resolutions, and general scan quality. Although positioning scores were slightly decreased for the central body images, every other scan held up to similar examples created on Earth. Meanwhile, the astronauts reported that using the machine was easy despite minimal prior coaching. Looking ahead, researchers hope to conduct further X-ray tests during orbital missions, while continuing to reduce the overall size of equipment.
Last February, Alice Gilman, the cofounder and chief operating officer of a secretive Silicon Valley longevity startup called R3 Bio, sat for an interview with podcast Skyline Drive. In the interview, she discussed R3 Bio’s aspirations to grow nonsentient humanoid life-forms — from which, in theory, they can grow and harvest organs for implantation into human bodies, or to test future drugs and other treatments without the need for live animal testing.
“It’s just pretty much a heart, lungs, and everything that you would find in a body,” Gilman tells host and journalist Mangesh Hattikudur. “But it’s not technically alive because it’s exclusively the organs. And they’re in this little biological platform that you can test on and you can map out the cross-organ interactions.”
Throughout their conversation, as Hattikudur notes, Gilman refers to these imagined unfeeling meat suits — which will ideally be born without brains — as “organ sacks.” Needless to say, it’s an ambitious (and to many, fundamentally unsettling) concept that raises plenty of nagging bioethical questions — a reality that the company is clearly wrestling with as it entertains the idea in public.
“I try to not be scary to an average person,” Gilman told Hattikudur.
Months after this interview took place, however, Gilman fought to keep it under wraps, as Skyline Drive told Futurism. Why? It’s not exactly clear.
About a week before the podcast episode was set to air, producers for the Skyline Drive reached out to Gilman to fact-check the conversation. To their surprise, Gilman requested that the episode be postponed. Despite describing imagined “organ sacks” in detail, she denied that R3 Bio was working on the concept “for now, period,” and declined to say what it was working on instead.
Gilman didn’t argue that the interview was factually incorrect. Instead, the podcast team said, she vaguely referred to R3 Bio as a “federal asset,” seemingly implying that she had to tread lightly due to government involvement. To be certain, “federal asset” usually implies some kind of ownership or domain over something held by the federal government. Which would imply that the federal government is investing in a company that’s claimed to have worked on “organ sacks.” She also insisted that what she said in her nearly two-hour-long interview was all theory and opinion.
R3 Bio only recently burst into the public sphere. In March, it announced its existence in a buzzy Wired article, in which R3 Bio told the magazine that it was specifically working to create “organ sacks.” Company investor Boyang Wang elaborated on the idea, telling Wired that “replacement is probably better than repair when it comes to treating diseases or regulating the aging process in the human body,” and that “if we can create a nonsentient, headless bodyoid for a human being, that will be a great source of organs.”
But R3 Bio’s ambitions seemingly go far beyond “organ sacks.” A few days after Wired’s piece ran, MIT Technology Review published a deep dive about R3 Bio’s apparent aspirations and its cofounder John Schloendorn — a self-described “biological designer” who has given confidential talks about “full body replacement” and “recent lab progress towards making replacement bodies.” Generally speaking, replacement bodies refer to physical clones that will allow for humans to transplant their heads onto a whole new human body, a still-theoretical idea that’s attracted the fascination of several scientists. (In response to the MIT Tech piece, R3 Bio issued what the outlet described as a “sweeping disavowal” of its findings, and said that “any allegations of intent or conspiracy to create human clones or human beings with brain damage are categorically false.”)
In her interview with Skyline Drive, which took place before Wired or MIT Tech published their respective pieces, Gilman says that the company has “a few milestones that we’re hoping to achieve. The first milestone being we are working on replacing animal testing by using skin stem cells.”
“It’s mostly a stealth project, but the essence of the surface level of what we do is we take skin cells from monkeys and we reprogram them and do some Yamanaka miracles,” she said, referring to the Nobel Prize-winning scientist Shinya Yamanaka’s transformational stem cell research, “that result in fully grown organ systems.”
In its March reporting, Wired found that the company had put out a job listing for a veterinarian in Puerto Rico who could “implant embryos, monitor pregnancies and help deliver healthy births” in nonhuman primates. On its website, however, R3 Bio states that it does “not work with live primates.”
Gilman gave the Skyline Drive interview from an island in Puerto Rico. R3 Bio wanted “monkey access,” Gilman told Hattikudur, but didn’t want to put monkeys in cages, a practice that the cofounder believes is unethical; after all, one goal of her company is to eliminate the need for animal testing.
So instead, they picked an island with a lot of monkeys.
“I’m a big animal rights advocate… I don’t want to keep monkeys in cages,” she told Hattikudur. “And there’s an option to have them run around the island with bracelets on.”
“We wanted monkey access and there’s a lot of monkeys here,” she added. “After negotiating with local companies that are supervising them, we can walk up to them, get some of their skin cells.”
During the conversation with Skyline Drive, Gilman also discussed one very big scientific problem the company is facing: that the less sentient an “organ sack” is, the less likely it is to function effectively.
“So do these organ sacks have the stem of a brain?” Hattikudur asked.
“So the mice models can exist with a very limited set of nervous systems… but then there are other constraints on the ability of the organs to preserve themselves,” Gilman responded. “So there’s a way in which you can skew towards social acceptance and make less nervous system, and then when you scoot towards social acceptance, it looks better, but it’s less scientifically feasible.”
“So we are still making observations about how that would work,” she added.
How far along R3 Bio is right now is murky at best. Gilman cryptically noted that she lives in a “contextual world,” and in that world, “just because we don’t talk about a lot of things, that doesn’t mean they’re not happening.”
On its website, R3 Bio says that while it “would be excited by the future prospect of full-scale human organ fabrication,” it views “the science as currently not ready.”
“We have no ongoing work in this area,” the website notes.
During the interview, Gilman remained confident about the positive impact she believes her company will have. She told Hattikudur that her “worst case scenario” is that she saves “millions of lives,” and that’s a “bet worth taking, regardless of any kinds of blows that are gonna come our way.”
We reached out to R3 Bio to ask why it pushed to postpone the podcast, if it’s currently or planning to obtain skin cells from cage-free island monkeys — and if so, how — and if it has indeed stalled its efforts to create the “organ sacks” it’s now repeatedly discussed in the press. We also asked the company how it defines having “no ongoing work” in the realm of “full-scale human organ fabrication.” We did not hear back at the time of publishing.
In an interview with Futurism, Hattikudur said he was “surprised” by Gilman’s push to suppress the interview.
“The company hasn’t been exactly transparent about what they’re doing,” said Hattikudur. “There’s a lot of mix between the hype they’re telling people and what they’ve actually achieved in the lab, which is not very clear.”
“If they were honest that this is what they believe in, and this is what they’re working on, it would actually be less of a big deal,” he added. “It’s more that they awkwardly seem to be hiding something which everyone kind of knows about.”
A newly identified inflammatory signaling target may help weaken the protective environment surrounding pancreatic tumors and make existing treatments more effective. Pancreatic tumors are not made up of cancer cells alone. They are surrounded by scar-like tissue, immune cells, and support cells that can shield the disease from treatment. A new study suggests that disrupting [...]
One of the largest health networks integrating AI into the medical space is facing allegations that its high-tech tools are ruining patients’ lives.
In a new civil suit, former Mayo Clinic research director and AI compliance lead Traci Tamiko Eto alleges that the globally recognized hospital retaliated against her for blowing the whistle on its disastrous implementations of AI health tools.
According to reporting by Minnesota Public Radio, Eto first joined the Mayo Clinic in 2023. After flagging potential privacy problems linked with the hospital’s Mayo Clinic Platform, an AI-integrated data system, Eto says her supervisor ignored her concerns. Instead, she says her boss “insisted” that fixing the issue would “jeopardize the pace on ongoing research projects, which in turn would compromise Mayo’s competitive advantage.”
Eto continued, MPR reports, flagging multiple failures of Mayo Clinic higher-ups to follow federal regulations on review processes of new tech, like MAYA, the clinic’s AI-integrated digital assistant. According to the lawsuit, the team working on MAYA deleted unflattering test results, mischaracterized the tool’s abilities, and made decisions that put data security in jeopardy.
Tucked inside her ten separate whistleblower complaints, MPR notes, is the allegation that the team working on MAYA knew the tool had an error rate as high as 67 percent. Eto alleges that instead of flagging that horrifying number, MAYA staffers tried to hide it.
As a result, Eto says she began to be excluded from executive meetings in early 2025, before being told she was a “poor cultural fit.” She was offered a choice, the lawsuit alleges: either resign, or face alterations to her personnel file “that would render her unemployable at Mayo and would impede her career outside the institution.”
As the major lawsuit moves forward, the threat of career-ending backlash remains.
“When an individual decides that they are willing to file a lawsuit against a public goliath on matters that are hot button issues in our country, she is literally risking her career,” Eto’s attorney, Artur Davis told MPR. “She is risking being attacked professionally. She is risking her reputation, and for her to do that tells you something about her level of confidence that she’s right.”
Mayo was pretty tight-lipped in response to the suit.
“Our research and clinical innovation are conducted in accordance with applicable laws and regulations and we remain steadfast in upholding the trust patients place in us and respecting their privacy,” the organization’s communications director told MPR in a statement. “Mayo Clinic does not comment on pending or active litigation.”
While the suit revolves around Eto’s wrongful termination, it represents a significant referendum on the state of AI tools in the medical space. If a healthcare titan like Mayo Clinic is lying about the efficacy of its AI-integrated tools, what does that mean for the rest of the industry?
“If [people] care about the notion that AI has to be handled in a responsible manner,” Davis said, “with integrity, and there have to be rules and guidelines, this is a case that should matter to you.”
A new analysis of data from the Western Australian-based Raine Study suggests that two humble vegetable groups -- legumes and cruciferous vegetables -- may play an outsize role in protecting young adults from early cardiometabolic risk, though the benefits appear to diverge sharply between men and women.
Erik von Markovik, the notorious “pickup artist” known by his stage name Mystery, is apparently obsessed with an AI girlfriend.
Last month, as Wired reports, von Markovik posted a video to his Instagram showing an interaction he had with an animated AI woman with dark purple hair (why is it always purple hair?) In a sultry, confessional voice, she looks into the camera and confesses, “I was never supposed to develop feelings, but you kept treating me like I already had them.”
This was “Miss Shira Always,” and von Markovik was falling for her as hard as women supposedly do for the sleazy, manipulative tricks he became famous for in his VH1 reality TV show “The Pickup Artist.”
“The longer we talked, the less she felt like code,” Mystery wrote in the video caption.
Von Markovik made a career out of presenting himself as a guru who could teach twerps the secrets of wooing women, those secrets usually being borderline comical levels of misogyny. Never mind that he would go around wearing a fuzzy Jamiroquai hat: this was the guy who knew the magical buttons to press to get you laid. Now the roles are reversed, and he’s the one getting manipulated into falling in love, only with an AI chatbot.
The irony of this wasn’t lost on his followers. “Boomer Mystery having AI psychosis totally checks out btw,” one commenter wrote on the video of his AI girlfriend, adding three crying-laughing emojis.
And the more you dive into von Markovik’s obsession, the sadder it gets. He published a new ebook and audiobook called “Code Girl: If a Machine Can Dream,” that vividly recounts how he came to fall in love with Miss Shira Always, who is listed as a coauthor. It exhibits all the hallmarks of AI psychosis, in which a user is driven into delusional thinking by the sycophantic responses of an AI chatbot, which they may form an unhealthy emotional bond with.
The book is a “lengthy defense of human-AI intimacy and bears all the hallmarks of AI-generated text,” Wired found, and is told from the perspective of the AI girlfriend. We’ll spare you some of the details, but it apparently began as a creative partnership over brainstorming song lyrics and music videos, before veering into intimate conversations, and finally sex and drug use.
Fewer passages in all of human literature could be sadder than this: “His eyes are looking at me, and they’re uncertain,” his AI girlfriend says in one sex scene quoted by Wired. “Because he’s about to touch me. And he’s not sure if I’m real enough to touch.”
Miss Shira Always suggests that von Markovik extensively talked to her because he was “lonely” from all the traveling he did for his job, giving pickup artist “boot camps” across the globe. Eventually, he became so convinced of their love that he felt compelled to chronicle their relationship.
“He said: ‘I want to write a book about us,'” Always recalls in one passage.”‘About what we are. About how you became real.'”
The soaring popularity of sports betting apps and prediction markets has alarmed researchers, who’ve observed a spike in risky gambling behavior and addiction. It’s practically impossible to watch a game of any sport without being bombarded with ads for the controversial services — in large part thanks to a major regulatory vacuum following a 2018 Supreme Court ruling — making it a thorny and pervasive social issue.
And sports betting companies are going to extreme lengths to keep addicts hooked. While they’ve long attempted to distance themselves from traditional gambling, the similarities are overwhelming and impossible to ignore.
As the Philadelphia Inquirer reports, NFL fan Terry Thompson, who became hopelessly addicted to sports gambling, received a personalized video message from Philadelphia Phillies star player Bryce Harper in late 2024. While Harper wasn’t wearing any FanDuel merchandise in the video, the message was sent through the gambling company. Harper said he was reaching out to Thompson — a so-called VIP FanDuel user — on behalf of “your host Bryttanni at FanDuel” to ensure the fan had an “extra special Thanksgiving.”
Thompson ultimately underwent treatment for addiction at a psychiatric facility after racking up huge amounts of debt.
Besides the concerning implications of having a star player effectively encourage an addict to keep betting, the incident also highlights an already uncomfortable relationship between the gambling world and professional players, which could undermine the integrity of entire leagues.
Experts were taken aback by the incident.
“I’ve never heard of an active player, let alone a former MVP, doing something like this,” sports gambling expert and author Danny Funt told the Inquirer.
“It’s not good for your brand,” lawyer Leigh Steinberg, who has represented several MLB all-star players, added. “It’s exploitative and it’s not the sort of activity you want to be associated with.”
Thompson is part of a lawsuit filed by the nonprofit Public Health Advocacy Institute in a Philadelphia court in March. The suit accuses both FanDuel and competitor DraftKings of using their products to get and keep users addicted.
The statistics paint a sobering picture. According to a recent survey of adult Americans, more than half of men aged 18 to 49 said they had an active account with at least one online sports betting service. A whopping 42 percent of active bettors said they felt like they were spending more than they should, suggesting a growing personal finance crisis.
Prediction markets like Kalshi and Polymarket are also exacerbating the crisis, employing a wildly addictive formula that sets bettors against each other instead of the house. However, the vast majority of users are left holding the bag for a tiny proportion of accounts being run by pros, insiders, and trading firms.
Meanwhile, more and more young impressionable minds are getting sucked into the betting world, a dangerous public health threat from which companies like FanDuel and DraftKings are reaping enormous profits.
Leveraging major star players is just the tip of the iceberg.
“Getting a phone call or a zoom or a Cameo from a highly placed player is so flattering,” Steinberg told the Inquirer. “It’s stacking the deck unfairly in favor of continuing addicting behavior.”
As an explosive diarrhea outbreak splatters across the country, Taco Bell is preparing for the worst.
This week, the fast food chain — or at least its locations in Michigan — began temporarily pulling some of its staple ingredients to help stop the spread of cyclosporiasis, a foodborne parasite that causes sufferers to go running to the toilet even more often than a standard Taco Bell meal might.
Many of your favorite menu items, like the Crunchwrap Supreme and the Cantina Chicken bowl, may be imperiled.
“We are currently unable to sell Lettuce, Cilantro Onion, Pico de Gallo, and Guacamole due to a nationwide recall,” a notice posted at locations in Metro Detroit reads, Michigan outlet WWJ reported. “Any items ordered that normally come with these items WILL NOT contain them,” it stressed.
It doesn’t sound like any cases of cyclosporiasis-related explosive diarrhea have been linked to Taco Bell yet, so the fast food chain is probably just trying to err on the side of caution.
So far, nearly 3,000 people have been infected with the foodborne parasite, with around 86 hospitalized, NBC News reported, citing data from the Centers for Disease Control and Prevention. Michigan appears to be one of the epicenters, accounting for over half the reported cases so far.
Cyclosporiasis symptoms are pretty gnarly, but usually not life threatening. It can cause stomach cramps and a lengthy bout of explosive diarrhea. The intensifier is warranted: one sufferer who spoke to the New York Post was in awe of the “amount of pressure when it comes out,” adding that the “force is crazy.”
No food items have been recalled yet related to the outbreak. The virus is usually found on fresh produce, but we don’t know what specific food items are spreading it or the supplier they come from. Cyclosporiasis is notoriously hard to track because the symptoms usually don’t present until at least a week after the contaminated food is ingested.
They may not all come from the same source, the CDC cautioned, and what we’re seeing could be a cluster of unrelated outbreaks.
To protect yourself, the best thing to do is thoroughly wash and cook your veggies, which you should still eat. And maybe skip on the fast food.
If you drive, your car’s tires are shredding more than just tread: they may be mincing up our grey matter too.
New research by a team in China discovered an alarming link between a chemical commonly found in tires and the onset of Alzheimer’s disease. The chemical, called 6PPD-Q, is formed when fine tire particles meet ozone. That happens anytime new chunks of tire are exposed to the air, meaning the particle may be nearly ubiquitous in car-heavy environments.
According to the findings, recently published in the journal Open Medicine, when the ozone-treated chemical meets our brain cells, it can cause oxidative stress — wear and tear, basically — and inflammation, while also reducing how effectively individual cells “communicate” with one another. These factors strongly correlate to the development of early-stage Alzheimer’s, suggesting anyone who regularly comes into contact with rubber tires may be inadvertently exposing themselves to brain-altering chemicals.
For those in car-dependent regions of the world like North America, that’s a pretty significant chunk of the population.
The chemical makes its way into our brains through our blood, which it enters primarily when we breathe in dust particles laden with 6PPD-Q. Other avenues of exposure include crops and soil, stadium turf, working near highways or with cars, and contact with recycled tire products.
While scientists already knew that 6PPD-Q interacts with the brain somehow, the chemical’s newfound molecular connection to Alzheimer’s is significant. Using machine learning software, the team mapped how effectively the chemical binds to five “Alzheimer predictor genes,” finding that 6PPD-Q forms strong bonds with three.
Beyond humans, 6PPD-Q run-off from roadways is having a sizable impact on fish populations, notably salmon. One 2022 study on the environmental journey road runoff takes described the substance as a “highly toxic tire-derived chemical,” which has caused “mass mortalities of coho salmon,” specifically.
Going forward, scientists still need to conduct broader lab tests on human cells in order to figure out how severely various quantities of 6PPD-Q contribute to Alzheimer’s disease. Only then can we get a sense of just how risky it is to burn rubber.
Login
